Compare Novartis AG (NVS) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Palo Alto Networks Inc — how do they compare? Novartis AG trades at $137.69 (market cap $262.64B), while Palo Alto Networks Inc trades at $336.2 (market cap $274.64B). The key difference: Novartis AG and Palo Alto Networks Inc are close in size by market cap, and Novartis AG pays a 3.44% dividend while Palo Alto Networks Inc pays none. Which is the better fit depends on your goals.
| NVS | PANW | |
|---|---|---|
Market Cap | $262.64B | $274.64B |
Sector | Health | Technology |
52-Week High | $168.62 | $396.00 |
52-Week Low | $121.80 | $141.67 |
Enterprise Value | $303.97B | $273.60B |
Dividend Yield | 3.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
Palo Alto Networks (PANW) trades at $336.98, up 1.12% today, with a bearish technical signal despite recent earnings beats. Revenue grew to $9.22B in FY2025, with strong gross margins of 71.94%, but valuation ratios are elevated (P/E 293.03, P/S 23.39). The company is set to join the S&P 500, reflecting its leadership in AI cybersecurity, though rising costs and premium pricing pose challenges.
Outlook remains positive due to AI-driven security demand and platformization strategy, but high valuation and competitive pressures warrant caution. Analyst consensus is bullish with a $410.48 price target, yet near-term volatility may persist as the stock digests recent gains and faces execution risks in a dynamic cybersecurity landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
